People
Multiple reports suggest an exodus of BIO team members over price control issues. BIO reorganized its leadership structure to provide what was expected to be “long-term stability for the organization.”
Marion Gruber, director of the agency’s Office of Vaccines Research & Review is leaving at the end of October. Phil Krause, OVRR’s deputy director, is exiting in November.
This is an effort to eliminate severe adverse reactions by matching the birth control to the genetics and hormones of the individual.
As CEO, Stolpe has presided over some highs with the launch of JAK1 inhibitor Jyseleca (filgotinib) in Europe, as well as the devaluation of the company’s share price by 70%.
Teva announced the appointment in a filing with the U.S. Securities and Exchange Commission. Zaks will serve on the board’s Science and Technology Committee.
The burgeoning genetic capabilities were instrumental in causing Semigran to transition into the biotech industry.
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
While the biotech market sees a high demand for the chief medical officer role, one Massachusetts oncology player has deemed the role completely unnecessary.
Pfizer Chief Executive Officer Albert Bourla tapped Aamir Malik to serve as the company’s chief business innovation officer.
BioSpace recently spoke with Yoav Kimchy, founder and chief technology officer of Check-Cap, a company developing the C-Scan® system to detect precancerous polyps.
PRESS RELEASES